Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „eGFR“
Suchtreffer
Begriffe & Kennungen
Avastin · 4.5 · 9 the randomised phase III studies, PACCE and CAIRO-2, in patients with mCRC suggest that the use of anti-EGFR
Eintrag öffnenAvastin · 4.5 · EGFR monoclonal antibodies in combination with bevacizumab chemotherapy regimens No interaction studies have b
Eintrag öffnenBosulif · 4.8 · Renal disorders In the paediatric study, 45 (82%) of the total 55 patients had normal eGFR (≥ 90 mL/min/1.73 m
Eintrag öffnenCinnarizin
Eintrag öffnenForxiga · 4.8 · In the DAPA-CKD study, eGFR decreased over time in both the dapagliflozin group and the placebo group. The ini
Eintrag öffnenForxiga · 4.8 · In the DAPA-HF and DELIVER studies, eGFR decreased over time in both the dapagliflozin group and the placebo g
Eintrag öffnenForxiga · 4.8 · In the DECLARE study, including elderly patients and patients with renal impairment (eGFR less than 60 mL/min/
Eintrag öffnenGefäß-Endothel-Wachstumsfaktor-Rezeptor 1
Eintrag öffnenGefäß-Endothel-Wachstumsfaktor-Rezeptor 2
Eintrag öffnenGefäß-Endothel-Wachstumsfaktor-Rezeptor 3
Eintrag öffnenGene, erbB-1-
Eintrag öffnenGiotrif · 4.8 · Summary of the safety profile The types of adverse reactions (ADRs) were generally associated with the EGFR in
Eintrag öffnenInvokana · 4.8 · 13 placebo group (2.60 events per 100 patient-years); however, in the subgroups eGFR ≥45 to <60 and eGFR 60 to
Eintrag öffnenInvokana · 4.8 · Patients treated with canagliflozin regardless of baseline eGFR experienced an initial fall in mean eGFR. Ther
Eintrag öffnenInvokana · 4.8 · The incidence rates for larger decreases in eGFR (> 30%) at any time during treatment were 7.3, 8.1, and 6.5 e
Eintrag öffnenMvasi · 4.5 · EGFR monoclonal antibodies in combination with bevacizumab chemotherapy regimens
Eintrag öffnenMvasi · 4.5 · No interaction studies have been performed. EGFR monoclonal antibodies should not be administered for the trea
Eintrag öffnenPradaxa · 4.3 · • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 • eGFR < 50 mL/mi
Eintrag öffnenSelincro · 4.3 · Patients with severe renal impairment (eGFR <30 ml/min per 1.73 m2).
Eintrag öffnenSteglatro · 4.8 · In VERTIS CV, treatment with ertugliflozin was associated with an initial decrease in mean eGFR (at Week 6, -2
Eintrag öffnen